Some of the more recent efforts in tuberculosis (TB) and trypanosomiasis drug discovery from both Product Development Partnerships (PDPs) and academia are highlighted in this this volume. Drug discovery approaches include both target- and phenotypic whole cell screening- approaches. Regarding the latter, mechanism of action studies through target identification are also illustrated.

Herbal, Bio-nutrient and Drug Titration According to Disease Stages in Integrative Cardiovascular Chinese Medicine, the first volume in the Integrative Cardiovascular Chinese Medicine series, provides a comprehensive guide to improving outcomes with cardiovascular medicine therapy options. Coverage includes the three types of medicines used in disease stage treatment, Chinese medicine, nutritional supplements and pharmaceutical drugs. All sections are organized according to drug class in western medicine and chapters in each section are organized according to disease stage, providing ease in navigation and reference within the book. This important reference will aid cardiovascular researchers in the study of integrative Chinese and western medicine as well as provide a clear, structured base to guide clinical practice and encourage collaboration between Chinese and Western medicine practitioners.

Neuropsychotherapeutics, Volume 86, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field, with this updated edition including sections on Pharmacotherapy of psychiatric disorders, Allosteric mechanisms for neuropsychopharmacology, Lipid rafts, Rapid-acting antidepressants, mGlu2/3 receptor antagonists, Nitric oxide: antidepressant mechanisms and inflammation, Anxiety disorders, mGlu receptors and schizophrenia, mAChR ligands for schizophrenia and addiction, PDE10 inhibitors, Obsessive-compulsive disorder, Addiction disorders (including eating), Dopamine D1 PAMs as a New Mode for Treatment of Neuropsychiatric Disorders, and more.

Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more.

Pharmacology of Restless Legs Syndrome (RLS), Volume 84, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field on essential topics, with this volume presenting chapters on Targeting the adenosinergic system in Restless Legs Syndrome, Assessing iron uptake mechanisms in the brain: impact of gender and genotype, Pharmacological treatments of RLS in augmentation, C. elegans and its applicability to studies on RLS, The neurophysiology of hyperarousal in RLS: hints for a role of glutamate/GABA, Treatment management and options in RLS patients, Pharmacological responsiveness of Periodic Legs Movements during Sleep, and more.

The high failure rate in the pharmaceutical industry has positioned biomarkers and personalized medicine in the frontline, as possible solutions. If executed right, biomarkers and companion diagnostics (CDx) can potentially help the drug industry enhance the probability of success, accelerate the time to market, and, more importantly, benefit patients by supporting accurate diagnosis and selection of the most effective and least toxic therapies. This book aims to examine the challenges and limitations in biomarkers and laboratory tests. It also offers advice on best practices to ensure proper application of biomarkers and bridges the gap between diagnostic business development claims and real-life deliverables. The book covers biomarkers for different purposes, provides examples from different technologies, which includes standard-of-care approved assays as well as for-investigational-use and for-research-use-only assays. It also includes new data for biomarkers in different therapeutic indications and offers case studies and practical examples. This book serves as a reference to drug developers, IVD providers, clinical labs, healthcare givers, academicians, and researchers for best practices to help increase the probability of success in drug development and improve patient management.

The Mechanics of Inhaled Pharmaceutical Aerosols: An Introduction, Second Edition provides a concise, but thorough exposition of fundamental concepts in the field of pharmaceutical aerosols. This revised edition will allow researchers in the field to gain a thorough understanding of the field from first principles, allowing them to understand, design, develop and improve inhaled pharmaceutical aerosol devices and therapies. Chapters consider mechanics and deposition, specifically in the respiratory tract, while others discuss the mechanics associated with the three existing types of pharmaceutical inhalation devices. This text will be very useful for academics and for courses taught at both undergraduate and graduate levels. Because of the interdisciplinary nature of this book, it will also serve a wide audience that includes engineers and scientists involved with inhaled aerosol therapies.

Polymer-Drug Conjugates: Linker Chemistry, Protocols and Applications discusses important concepts, fundamentals and prospective applications of 'Linker Chemistry' in a clear-and-concise manner. The book provides vital information on chemical entities binding with the drug-polymer complex for targeted drug delivery systems. It highlights roles and significance, different classes and synthetic protocols as well as mechanisms of chemical bond formation in drug-polymer conjugation in drug delivery, also offering insights into the mechanism of polymer interaction with linker and drug molecules by biodegradable chemical bonding. The protocol of binding with drug molecules is clearly explained and justified with case studies, helping researchers and advanced students in the pharmaceutical sciences understand fundamentals involved and related aspects in molecule designing for effective therapeutic benefits.

Bioactive Lipid Mediators in Cardiopulmonary Pharmacology, Volume 97 updates readers on topics surrounding Bioactive lipid mediators. These mediators are involved in a vast array of signaling pathways that regulate both physiological and pathophysiological responses. Chapters in this new release include Cyclooxygenases and Vascular Function, Cyclooxygenases and Platelet Function, Eicosanoids and Cardiomyopathies, Cytochrome P450 Bioactive Lipids in the Heart, Epoxide Hydrolase and Leukotoxin in the Heart and Lung, Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response, Bioactive Lipids in Hypertension, Cytochrome P450 Metabolites and Angiogenesis, 20-Hydroxyeicosatetraenoic Acid and Vascular Function, and more. Other critical sections cover Cytochrome P450 Eicosanoids and the Brain, Omega-3 Oxylipids, Resolvins, Lipoxins and Inflammation, Endocannabinoids as Bioactive Metabolites, and Oxylipins and Aspirin Exacerbated Respiratory Disease.

This is a timely and essential companion to the recently published Antimicrobial Resistance in the 21st Century, Second Edition. Antimicrobial resistance is a major threat to global population health, with government reports projecting it could result in over 10 million deaths in the next 35 years. Development of new agents to combat this threat is one of the WHO's top priorities, but in 2017, it conceded that the current drug development pipeline was insufficient to mitigate the threat. This book discusses recent progress and bolster new agent discovery and development, by providing researchers and students who will soon enter the field with a thorough guide to the advancements made in the last decade.  Coverage includes new systemic antimicrobials approved since 2010, with detailed analysis of antibiotics, antivirals, antifungals, and antiparasitics, as well as agents in development for future use. Discussion of each drug will include its chemical nature, pharmacology/pharmacokinetics, antimicrobial spectrum, dosage, adverse reactions, drug interactions, microbial resistance, indications, clinical efficacy compared to older agents, and lists of similar agents with cost comparison. This volume is designed for researchers and students of infectious disease and medical microbiology, as well as clinicians in need of a comprehensive guide to newly developed agents.